

# **Drug Addiction - Pipeline Review, H1 2020**

https://marketpublishers.com/r/D221FCAB40FEN.html

Date: February 2020

Pages: 221

Price: US\$ 2,000.00 (Single User License)

ID: D221FCAB40FEN

### **Abstracts**

Drug Addiction - Pipeline Review, H1 2020

#### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2020, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key



players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 12, 31, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 13 and 3 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

#### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and



understand from the know-how what drove them from pipeline.



# **Contents**

Introduction

Drug Addiction - Overview

Drug Addiction - Therapeutics Development

Drug Addiction - Therapeutics Assessment

Drug Addiction - Companies Involved in Therapeutics Development

**Drug Addiction - Drug Profiles** 

**Drug Addiction - Dormant Projects** 

**Drug Addiction - Discontinued Products** 

Drug Addiction - Product Development Milestones

Appendix



### **List Of Tables**

### LIST OF TABLES

Number of Products under Development for Drug Addiction, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Drug Addiction - Pipeline by Adjuvance Technologies Inc, H1 2020

Drug Addiction - Pipeline by Aelis Farma SAS, H1 2020

Drug Addiction - Pipeline by Amygdala Neurosciences Inc, H1 2020

Drug Addiction - Pipeline by Aphios Corp, H1 2020

Drug Addiction - Pipeline by Astellas Pharma Inc, H1 2020

Drug Addiction - Pipeline by Astraea Therapeutics LLC, H1 2020

Drug Addiction - Pipeline by BioCorRx Inc, H1 2020

Drug Addiction - Pipeline by Camino Pharma LLC, H1 2020

Drug Addiction - Pipeline by Cerevel Therapeutics LLC, H1 2020

Drug Addiction - Pipeline by Charleston Laboratories Inc, H1 2020

Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H1 2020

Drug Addiction - Pipeline by Consegna Pharma Inc, H1 2020

Drug Addiction - Pipeline by Curemark LLC, H1 2020

Drug Addiction - Pipeline by D&A Pharma SAS, H1 2020

Drug Addiction - Pipeline by Daya Drug Discoveries Inc, H1 2020

Drug Addiction - Pipeline by DD Therapeutics LLC, H1 2020

Drug Addiction - Pipeline by Denovo Biopharma LLC, H1 2020

Drug Addiction - Pipeline by Elysium Therapeutics Inc, H1 2020

Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2020

Drug Addiction - Pipeline by EncepHeal Therapeutics Inc, H1 2020



Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Drug Addiction - Pipeline by Foresee Pharmaceuticals Co Ltd, H1 2020

Drug Addiction - Pipeline by IMV Inc, H1 2020

Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H1 2020

Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H1 2020

Drug Addiction - Pipeline by Kdac Therapeutics Inc, H1 2020

Drug Addiction - Pipeline by KemPharm Inc, H1 2020

Drug Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, H1 2020

Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020

Drug Addiction - Pipeline by MAKScientific LLC, H1 2020

Drug Addiction - Pipeline by MElkin Pharmaceuticals, H1 2020

Drug Addiction - Pipeline by Mind Medicine Inc, H1 2020

Drug Addiction - Pipeline by Mu Therapeutics Inc, H1 2020

Drug Addiction - Pipeline by NLS Pharma Group, H1 2020

Drug Addiction - Pipeline by Novartis AG, H1 2020

Drug Addiction - Pipeline by Omeros Corp, H1 2020

Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2020

Drug Addiction - Pipeline by Ovid Therapeutics Inc, H1 2020

Drug Addiction - Pipeline by P2D Inc, H1 2020

Drug Addiction - Pipeline by Paion AG, H1 2020

Drug Addiction - Pipeline by Protagenic Therapeutics Inc. H1 2020

Drug Addiction - Pipeline by Saniona AB, H1 2020

Drug Addiction - Pipeline by Sen-Jam Pharmaceutical LLC, H1 2020

Drug Addiction - Pipeline by Seropeutics LLC, H1 2020

Drug Addiction - Pipeline by Sosei Heptares, H1 2020

Drug Addiction - Pipeline by SpringWorks Therapeutics Inc, H1 2020

Drug Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020

Drug Addiction - Pipeline by Vallon Pharmaceuticals Inc, H1 2020

Drug Addiction - Pipeline by Zelira Therapeutics Ltd, H1 2020

Drug Addiction - Pipeline by Zyla Life Sciences, H1 2020

Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2020

Drug Addiction - Dormant Projects, H1 2020

Drug Addiction - Dormant Projects, H1 2020 (Contd..1), H1 2020

Drug Addiction - Dormant Projects, H1 2020 (Contd..2), H1 2020

Drug Addiction - Dormant Projects, H1 2020 (Contd..3), H1 2020

Drug Addiction - Discontinued Products, H1 2020



# **List Of Figures**

### LIST OF FIGURES

Number of Products under Development for Drug Addiction, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### **COMPANIES MENTIONED**

Adjuvance Technologies Inc

Aelis Farma SAS

Amygdala Neurosciences Inc

**Aphios Corp** 

Astellas Pharma Inc

Astraea Therapeutics LLC

BioCorRx Inc

Camino Pharma LLC

Cerevel Therapeutics LLC

Charleston Laboratories Inc.

Chiesi Farmaceutici SpA

Consegna Pharma Inc

Curemark LLC

D&A Pharma SAS

Daya Drug Discoveries Inc

DD Therapeutics LLC

Denovo Biopharma LLC

Elysium Therapeutics Inc

Embera NeuroTherapeutics Inc

**EncepHeal Therapeutics Inc** 

F. Hoffmann-La Roche Ltd



Foresee Pharmaceuticals Co Ltd

IMV Inc

InterveXion Therapeutics LLC

Intra-Cellular Therapies Inc

Kdac Therapeutics Inc

KemPharm Inc

Kinoxis Therapeutics Pty Ltd

Kyorin Pharmaceutical Co Ltd

MAKScientific LLC

MElkin Pharmaceuticals

Mind Medicine Inc

Mu Therapeutics Inc

NLS Pharma Group

Novartis AG

**Omeros Corp** 

Orexigen Therapeutics Inc

Ovid Therapeutics Inc

P2D Inc

Paion AG

Protagenic Therapeutics Inc

Saniona AB

Sen-Jam Pharmaceutical LLC

Seropeutics LLC

Sosei Heptares

SpringWorks Therapeutics Inc

Tonix Pharmaceuticals Holding Corp

Vallon Pharmaceuticals Inc

Zelira Therapeutics Ltd

Zyla Life Sciences

Zynerba Pharmaceuticals Inc



### I would like to order

Product name: Drug Addiction - Pipeline Review, H1 2020

Product link: https://marketpublishers.com/r/D221FCAB40FEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/D221FCAB40FEN.html">https://marketpublishers.com/r/D221FCAB40FEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970